Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05AAD
|
||||
| Former ID |
DCL000323
|
||||
| Drug Name |
Isatoribine
|
||||
| Synonyms |
Immunosine; Immusine; Isatorabine; Satoribine; TOG; Isatoribine monohydrate; ANA 245; ANA245; N10146; ANA-245; ICN-10146; Immusine (TN); Isatoribine (USAN); Isatoribine [USAN:INN]; NARI-10146; 5-Amino-3-.beta.-D-ribofuranosylthiazolo[4,5]pyrimidine-2,7(3H,6H)-dione; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; 5-amino-3-(A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione; 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione hydrate; 7-Deaza-7-thia-8-oxoguanosine; 7-TOG; 7-Thia-8-oxoguanosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 2 | [522035] | ||
| Company |
Anadys Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H14N4O7S
|
||||
| Canonical SMILES |
C(C1C(C(C(O1)N2C3=C(C(=O)N=C(N3)N)SC2=O)O)O)O.O
|
||||
| InChI |
1S/C10H12N4O6S.H2O/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8;/h2-4,8,15-17H,1H2,(H3,11,12,13,18);1H2/t2-,3-,4-,8-;/m1./s1
|
||||
| InChIKey |
BZWQQOVSUSJJJO-QAGDRQIHSA-N
|
||||
| CAS Number |
CAS 122970-40-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Toll-like receptor 7 | Target Info | Agonist | [536564] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Toll receptor signaling pathway | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.